Martha Shadan New President, CEO of Miach Orthopaedics

Martha Shadan, who has more than 30 years of medical device executive, marketing and commercialization expertise, has moved from her executive chairwoman position of Miach Orthopaedics to the president and CEO of the company.

Westborough, Massachusetts-based Miach Orthopaedics, Inc. has its first product under development—the Bridge-Enhanced ACL [anterior cruciate ligament] Repair (BEAR) technology, currently being studied in U.S. clinical trials.

During most of 2018, says the company, Shadan served as global vice president of marketing at Smith & Nephew plc, a role she assumed after the company acquired Rotation Medical, where she was president and CEO. Shadan led the company through FDA approval and commercialization of the Rotation Medical Bioinductive Implant for rotator cuff tears (now known as REGENETEN), as well as the company’s acquisition by Smith & Nephew in December 2017.

“We are very glad to have Martha Shadan joining the Miach team,” said Martha Murray, M.D., founder and chief medical officer of Miach Orthopaedics. “Her experience in the medical device space with successful commercialization of medical devices brings in a very valuable skill set, and we are very much looking forward to working with her as the CEO.”

Shadan has held senior leadership positions at Zimmer, Covidien, Bristol Myers Squibb Co. and Merck Millipore. Since 2017 she has served on the Board of Directors of the Advanced Medical Technology Association, and she is chairwoman of the Accel Board of Directors chairwoman. She is a founding member of the Leadership Circle for the Women’s Executive Network (WEN). Shadan holds a Master of Business Administration from Northeastern University, a Master of Science in Biology from Michigan State University, and a Bachelor of Science in Biology from the University of New Hampshire.

Shadan told OTW, “The potential of providing a new approach to ACL repair is exciting, and my first steps with Miach Orthopaedics are to build out the company’s infrastructure while clinical trials of our BEAR technology continue. ACL reconstruction surgery is one of the most common orthopaedic procedures in the U.S., and the clinical results we’ve seen to date are extremely promising. I look forward to working with the FDA on regulatory pathways and timelines as we take measured steps toward commercialization.”